Findings on a toxic HIV molecule pave way for clinical drug trial

What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never ...
EurekAlert!

The RESTART trial: a drug to block a toxic HIV molecule

What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never ...
Medscape

High Immune Activation in Patients With Undetectable Viral Loads and Low CD4-Cell Counts

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

Lifesaving new antibody blocks 98.5% of all known HIV strains

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly ...
The New England Journal of Medicine

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T ...